Medgenics Inc Registration of Shares (2469I)
July 23 2012 - 7:30AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 2469I
Medgenics Inc
23 July 2012
Press Release 23 July 2012
Medgenics, Inc.
("Medgenics" or the "Company")
Medgenics Announces Registration of Shares to be Issued Upon
Exercises of Warrants Listed on NYSE MKT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump(TM) , a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, today announced the availability of a current
prospectus following the effectiveness of its registration in the
United States of common stock issuable upon the exercise of
outstanding warrants to purchase 2,829,000 shares of common
stock.
The warrants were originally issued in the Company's initial
public offering in the United States in April 2011 and are listed
on the NYSE MKT (formerly the NYSE Amex) under the symbol
"MDGN.WS." Each warrant is exercisable for one share of the
Company's common stock, listed on the NYSE MKT under the symbol
"MDGN."
The shares of common stock issuable upon exercise of the
warrants are being offered by the Company pursuant to a
registration statement previously filed and declared effective by
the Securities and Exchange Commission on July 20, 2012. Electronic
copies of the prospectus may be obtained at the Securities and
Exchange Commission's website at http://www.sec.gov. Copies of the
prospectus may also be obtained from Corporate Stock Transfer,
Inc., as warrant agent, by contacting it at 3200 Cherry Creek Drive
South, Suite 4300, Denver, Colorado 80209, or (303) 282-4800.
In order to exercise a warrant, the holder must deliver to
Corporate Stock Transfer, Inc., 3200 Cherry Creek Drive South,
Suite 4300, Denver, Colorado 80209:
-- the original warrant certificate
-- a completed and executed exercise form located on the reverse
side of the warrant certificate and
-- full payment of the exercise price, by certified check
payable to "Medgenics Warrant Exercise Account" or by wire transfer
of immediately available funds.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis, and hemophilia, among others.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
andrew.pearlman@medgenics.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Nomura Code Securities (NOMAD and Phone: +44 207 776 1200
Joint Broker)
Jonathan Senior
Giles Balleny
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKXLBLLDFXBBD
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024